New ATC codes 2020
| ATC code | ATC level name |
|---|---|
| V04CX05 | 13C-urea |
| L01XE51 | acalabrutinib |
| L01XX65 | alpelisib |
| J05AX26 | amenamevir |
| C08CA51 | amlodipine and celecoxib |
| V03AF11 | arginine and lysine |
| C10BA08 | atorvastatin and omega-3 fatty acids |
| J05AX25 | baloxavir marboxil |
| L01XX68 | belotecan |
| C10AX15 | bempedoic acid |
| B01AF04 | betrixaban |
| S01LA06 | brolucizumab |
| V04CX08 | carbon monoxide |
| L01XC33 | cemiplimab |
| D03AX14 | Centella asiatica herba |
| B06AX01 | crizanlizumab |
| J05AP58 | daclatasvir, asunaprevir and beclabuvir |
| L02BB06 | darolutamide |
| J05AR26 | darunavir and ritonavir |
| L04AX08 | darvadstrocel |
| G01AF55 | econazole, combinations |
| V04CX07 | edrophonium |
| H01CC03 | elagolix |
| L03AX21 | elapegademase |
| J05AP10 | elbasvir |
| L01XX64 | entinostat |
| L01XE56 | entrectinib |
| J04AB06 | enviomycin |
| N06AX27 | esketamine 2) |
| J05AX27 | favipiravir |
| L01XE57 | fedratinib |
| B03AA12 | ferrous sodium citrate |
| C09DB09 | fimasartan and amlodipine |
| V04CX02 | folic acid |
| R03AL10 | formoterol and tiotropium bromide |
| R03AL11 | formoterol, glycopyrronium bromide and budesonide |
| N02CD03 | fremanezumab |
| L01XE54 | gilteritinib |
| L01XX63 | glasdegib |
| D11AA01 | glycopyrronium |
| J05AP11 | grazoprevir |
| V04CX06 | hexaminolevulinate |
| A03BB06 | homatropine methylbromide |
| L04AA41 | imlifidase |
| R03AK14 | indacaterol and mometasone |
| R03AL12 | indacaterol, glycopyrronium bromide and mometasone |
| N07XX15 | inotersen |
| C09DX07 | irbesartan, amlodipine and hydrochlorothiazide |
| L01XX62 | ivosidenib |
| J05AR25 | lamivudine and dolutegravir |
| J05AR27 | lamivudine, tenofovir disoproxil and dolutegravir |
| J05AH04 | laninamivir |
| L01XE53 | larotrectinib |
| S01EE51 | latanoprost and netarsudil |
| S01EE06 | latanoprostene bunod |
| J01XX12 | lefamulin |
| B03XA06 | luspatercept |
| V04CX04 | mannitol |
| V04CX03 | methacholine |
| V09IX13 | methionine (11C) |
| A03FA09 | mosapride |
| P02CX03 | moxidectin |
| J01AA15 | omadacycline |
| L04AB07 | opinercept |
| H02CA02 | osilodrostat |
| B06AX 1) | Other hematological agents |
| V04CX09 | patent blue |
| A16AB19 | pegvaliase |
| C09BX04 | perindopril, bisoprolol and amlodipine |
| J01GB14 | plazomicin |
| L01XE52 | quizartinib |
| A02BD12 | rabeprazole, amoxicillin and clarithromycin |
| A02BD13 | rabeprazole, amoxicillin and metronidazole |
| L04AA43 | ravulizumab |
| N05CD14 | remimazolam |
| R03BB08 | revefenacin |
| A07AA13 | rifamycin |
| D06AX15 | rifamycin |
| L04AC18 | risankizumab |
| C10BA09 | rosuvastatin and fenofibrate |
| C10BX16 | rosuvastatin and fimasartan |
| C10BA07 | rosuvastatin and omega-3 fatty acids |
| C10BX17 | rosuvastatin and ramipril |
| J01AA14 | sarecycline |
| L01XX66 | selinexor |
| L04AA42 | siponimod |
| N06BA14 | solriamfetol |
| A10BK06 | sotagliflozin |
| P01BA07 | tafenoquine |
| L01XX67 | tagraxofusp |
| G04CA54 | tamsulosin and tadalafil |
| J05AX24 | tecovirimat |
| B02AB05 | ulinastatin |
| L04AA44 | upadacitinib |
| S01AA28 | vancomycin |
| A02BD14 | vonoprazan, amoxicillin and clarithromycin |
| A02BD15 | vonoprazan, amoxicillin and metronidazole |
| A02BC08 | vonoprazan |
| S01XA27 | voretigene neparvovec |
1) New 4th level
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.
Last updated: 2019-12-20